85 related articles for article (PubMed ID: 22059804)
21. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.
Shoup M; Stojadinovic A; Nissan A; Ghossein RA; Freedman S; Brennan MF; Shah JP; Shaha AR
J Am Coll Surg; 2003 Aug; 197(2):191-7. PubMed ID: 12892796
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma.
Huang IC; Chou FF; Liu RT; Tung SC; Chen JF; Kuo MC; Hsieh CJ; Wang PW
Clin Endocrinol (Oxf); 2012 Mar; 76(3):439-47. PubMed ID: 21950769
[TBL] [Abstract][Full Text] [Related]
23. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
[TBL] [Abstract][Full Text] [Related]
24. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
25. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
26. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease.
Wan Nazaimoon WM; Khalid BA
Horm Metab Res; 1998 Apr; 30(4):213-6. PubMed ID: 9623636
[TBL] [Abstract][Full Text] [Related]
28. Thyroid function and cholesterol level: paradoxical findings in large groups of population with high cholesterol food intake.
Langer P; Kocan A; Tajtakova M; Petrik J; Koska J; Hucková M; Hanzen E; Ksinantova L; Radikova Z; Imrich R; Trnovec T; Blazicek P; Sebokova E; Klimes I
Endocr Regul; 2003 Sep; 37(3):175-80. PubMed ID: 14986723
[TBL] [Abstract][Full Text] [Related]
29. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.
Klein Hesselink EN; Klein Hesselink MS; de Bock GH; Gansevoort RT; Bakker SJ; Vredeveld EJ; van der Horst-Schrivers AN; van der Horst IC; Kamphuisen PW; Plukker JT; Links TP; Lefrandt JD
J Clin Oncol; 2013 Nov; 31(32):4046-53. PubMed ID: 24101052
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
31. [Thyroid function in depressed patients].
De Mendonça Lima CA; Vandel S; Bonin B; Bertschy G; Bizouard P
Encephale; 1996; 22(2):85-94. PubMed ID: 8706626
[TBL] [Abstract][Full Text] [Related]
32. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
33. Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.
Klubo-Gwiezdzinska J; Auh S; Gershengorn M; Daley B; Bikas A; Burman K; Wartofsky L; Urken M; Dewey E; Smallridge R; Chindris AM; Kebebew E
JAMA Netw Open; 2019 Feb; 2(2):e187754. PubMed ID: 30707227
[TBL] [Abstract][Full Text] [Related]
34. The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer.
Zou Y; Li B; Wang X; Mao J; Zhang Y
Medicine (Baltimore); 2022 Dec; 101(48):e31991. PubMed ID: 36482589
[TBL] [Abstract][Full Text] [Related]
35. Endogenous TSH levels at the time of
Vrachimis A; Riemann B; Mäder U; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):224-231. PubMed ID: 26493309
[TBL] [Abstract][Full Text] [Related]
36. Pattern analysis for prognosis of differentiated thyroid cancer according to preoperative serum thyrotropin levels.
Kim H; Jung J; Cho YS; Choi JY; Park H; Lee YB; Kim SW; Chung JH; Kim TH
Sci Rep; 2021 Nov; 11(1):22322. PubMed ID: 34785735
[TBL] [Abstract][Full Text] [Related]
37. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.
Pajamäki N; Metso S; Hakala T; Ebeling T; Huhtala H; Ryödi E; Sand J; Jukkola-Vuorinen A; Kellokumpu-Lehtinen PL; Jaatinen P
Clin Endocrinol (Oxf); 2018 Feb; 88(2):303-310. PubMed ID: 29154445
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Adrenal Reserve in Patients with Differentiated Thyroid Cancer Receiving Thyroid Hormone Suppression Therapy- case-control Comparative Study.
Bilginer MC; Tam AA; Faki S; Bestepe N; Dellal FD; Ozdemir D; Topaloglu O; Ersoy R; Cakir B
Endocr Res; 2023 Feb; 48(1):9-15. PubMed ID: 36524715
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Thyrotropin Suppression on Survival Outcomes in Patients with Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.
Gubbi S; Al-Jundi M; Foerster P; Cardenas S; Butera G; Auh S; Wright EC; Klubo-Gwiezdzinska J
Thyroid; 2024 May; ():. PubMed ID: 38717947
[No Abstract] [Full Text] [Related]
40. Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma.
Wang R; Yang L; Jin S; Han X; Liu B
Cancer Cell Int; 2018; 18():189. PubMed ID: 30479568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
